13D Filing: QVT Financial and Arbutus Biopharma Corp (ABUS)

Page 1 of 9

Arbutus Biopharma Corp (NASDAQ:ABUS): Daniel Gold’s QVT Financial filed an amended 13D.

You can check out QVT Financial’s latest holdings and filings here.

Please follow QVT Financial (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about QVT Financial or update its stock holdings.

Daniel Gold QVT Financial

Daniel Gold of QVT Financial

Follow Daniel Gold's QVT Financial

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
QVT Financial 0 0 0 16,013,540 16,013,540 29.1%
QVT Financial GP 0 0 0 16,013,540 16,013,540 29.1%
QVT Fund V 0 0 0 16,013,540 16,013,540 29.1%
QVT Associates GP 0 0 0 16,013,540 16,013,540 29.1%

Follow Daniel Gold's QVT Financial

Page 1 of 9 – SEC Filing

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

(Amendment No. 1)*

Under the Securities Exchange Act of 1934

Arbutus
Biopharma Corporation

(Name of Issuer)

Common Shares, no par value

(Title of Class of Securities)

03879J100

(CUSIP Number)

Eleazer Klein, Esq.

Schulte Roth & Zabel LLP

919 Third Avenue, New York, NY 10022

(212) 756-2000

(Name,
Address and Telephone Number of Person Authorized to Receive Notices and Communications)

October 16, 2017

(Date of Event which Requires Filing of this Statement)

If the filing person has
previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-l(e), 240.13d-l(f) or 240.13d-1(g), check the following box.  ☐

Note: Schedules filed in paper format shall
include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information
which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be
deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act
(however, see the Notes).

Follow Arbutus Biopharma Corp (NASDAQ:ABUS)

Page 1 of 9